Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study
Author:
Affiliation:
1. Department of Hematology Multiple Myeloma Medical Center of Beijing Beijing Chao‐yang HospitalCapital Medical University Beijing China
2. Department of Hematology Qingdao Municipal Hospital School of MedicineQingdao University Qingdao China
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4313
Reference23 articles.
1. Approaches to Treating Multiple Myeloma, Now and Moving Forward
2. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
3. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
4. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
5. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09
2. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation;Annals of Hematology;2023-03-08
3. Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone;Cancer Medicine;2022-09-02
4. Bortezomib Eliminates Persistent Chlamydia trachomatis Infection through Rapid and Specific Host Cell Apoptosis;International Journal of Molecular Sciences;2022-07-04
5. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results;Frontiers in Oncology;2022-05-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3